Trial Profile

A retrospective study of safety and the humoral response to a third booster dose of the BNT162b2 mRNA COVID-19 vaccine in patients with Multiple Sclerosis (pwMS) treated with Ocrelizumab (OCR) or Fingolimod

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Dec 2022 Results assessing Safety and efficacy of a third booster dose of BNT162b2 mRNA Covid-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod published in the Journal of Neurology
15 Nov 2022 New trial record
28 Oct 2022 Results presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com